# Three top-class smaller biotech firms to invest in

> Three smaller biotech firms show high growth potential with 2027 regulatory decisions.
- Title: Three top-class smaller biotech firms to invest in · MoneyWeek
- Summary: Three smaller biotech firms show high growth potential with 2027 regulatory decisions. Three smaller biotech firms have high growth potential with 2027…
- Keywords: united therapeutics, vaxcyte, palvella therapeutics, nasdaq, 2027, biotech stocks, regulatory decision, Three, top-class, smaller, biotech, firms
- Source: MoneyWeek — https://moneyweek.com/investments/biotech-stocks/three-top-class-smaller-biotechnology-companies
- Published: 2026-11-02T08:00:00+00:00
- Read time: 1 min
- Topics: united therapeutics, vaxcyte, palvella therapeutics, nasdaq, 2027, biotech stocks, regulatory decision
## Biotech innovation surge
Biotechnology companies see record innovation despite FDA staff turnover and patent expiries.
## Biotech Growth Trust strategy
The Trust invests in small and mid-sized biotech firms developing first-in-class medicines.
## United Therapeutics expansion
United Therapeutics expands into fibrosis market with Tyvaso expected to launch in spring 2027.
## Vaxcyte vaccine progress
Vaxcyte reported positive Phase III results for pneumococcal vaccine with 2027 pediatric data expected.
## Palvella Therapeutics target
Palvella targets 2027 launch for rapamycin gel for rare microcystic lymphatic malformations.
## 2027 regulatory milestones
All three firms expect key regulatory decisions in spring 2027 for potential market leadership.
## Key takeaway

Three smaller biotech firms have high growth potential with 2027 regulatory decisions.